Objective: The aim of this study was to characterize the ovarian primordial and nongrowing follicle number according to the Stages of Reproductive Aging Workshop (STRAW) staging system as defined by menstrual cycle characteristics.
T he development of a staging system for reproductive aging is of considerable interest to both researchers and clinicians to better predict the timing and duration of the menopausal transition and to standardize patient populations across studies. Ideally, such a system would include easily identifiable milestones for entry into progressively advanced stages of the menopausal transition and be highly reproducible across populations. 1, 2 In recognition of the need for such a staging system to address the medical and social consequences of reproductive aging, a sponsored workshop was held in 2001 to develop a reliable and useful staging system. The executive summary of this workshop created the Stages of Reproductive Aging Workshop (STRAW) staging system. 1 This system is anchored by the final menstrual period (FMP; Fig. 1 ) and consists of seven stages. Stages j5 to j3 represent the reproductive years, whereas stages j2 to j1 represent the menopausal transition. Advancement from one stage to the next is indicative of a shorter interval before the FMP and is categorized based on menstrual cycle characteristic changes ( Fig. 1) . Stages +1 and +2 represent the early and late postmenopause, respectively. Only one biochemical parameter, serum follicle-stimulating hormone (FSH), was included in the initial STRAW proposal.
The participants in the STRAW conference recognized that the STRAW staging system was an initial proposal that would need to be validated and modified as additional information became available. Toward that end, the ReSTAGE collaboration 3<5 has considerably improved our understanding of the menstrual cycle changes associated with the progression from one STRAW stage to the next through the empiric review of menstrual calendars from population-based cohorts, including TREMIN, Melbourne Women's Midlife Health Project, Seattle Midlife Women's Health Study, and Study of Women's Health Across the Nation. 6<9 In addition, statistically significant differences in levels of hormones, including FSH, inhibin B, and antimüllerian hormone (AMH), have been identified between the STRAW stages. 10<12 Unfortunately, because of the considerable overlap in serum levels of hormones, none of these endocrine markers are predictive of a specific STRAW stage. 11<13 The underlying anatomical change associated with the progressive decline in fertility and ovarian endocrine function associated with aging is ovarian follicle depletion. 14, 15 The basic ovarian follicle is the anatomic/functional unit of the ovary consisting of a primary oocyte and the surrounding granulosa cells. Many investigators consider the ovarian primordial follicle (PF) pool to constitute the ovarian reserve, whereas others consider the ovarian reserve to include the primordial as well as the intermediate and primary follicles. 16, 17 Altogether, this cohort of resting follicles is known as the nongrowing follicle (NGF) pool ( Fig. 2 ). Regardless of one's opinion on this issue, it is clear that the ovarian reserve encompasses one or all of these groups.
Given that the physiological basis for the reproductive aging process is ovarian follicle depletion, the ultimate validation of a staging system of reproductive aging would be the identification of significant differences in resting ovarian follicle numbers in women at different STRAW stages. Therefore, the goal of this investigation was to determine if significant differences in the ovarian PF and total NGF count exist between the STRAW stages as defined by menstrual cycle characteristics. To compare these observed differences in ovarian PF and total NGF count with commonly used clinical markers of ovarian reserve, we also examined endocrine and anatomical (the ovarian antral follicle count [AFC] as determined by transvaginal ultrasound examination) differences between the STRAW stages in a subset (n = 43) of the participants.
METHODS

Participants
As part of a series of investigations examining the agerelated depletion of ovarian PF and NGF associated with aging, we collected ovaries from 119 women undergoing elective oophorectomy for benign gynecologic indications between 2001 and 2011. All participants completed a detailed questionnaire regarding menstrual cycle characteristics. Of the 119 women, 63 (20 from the University of Washington, 43 from the University of Oklahoma) could be classified into the original STRAW staging system by their menstrual cycle characteristics and were not taking any hormonal preparations that may have altered menstrual cycles. Participants were classified according to the STRAW staging system 1 based on menstrual cycle characteristics only ( Fig. 1) , with the exception of stages j4 and j3, wherein women with regular cycles and who were 35 years or younger were considered stage j4 and those 40 years or older were considered stage j3. Serum levels of FSH could not be used to classify participants into the respective STRAW stages, as these measurements were obtained irrespective of cycle day because of the usual short time frame between enrollment and surgical operation. Before surgical operation, each participant enrolled at the University of Oklahoma underwent a transvaginal ultrasound examination for the determination of the ovarian AFC and venipuncture for the determination of serum levels of AMH, estradiol, inhibin B, and FSH and completed the informed consent process. Participants were recruited from patients undergoing benign gynecologic operation at the University of Oklahoma and the University of Washington. Exclusion criteria included gynecological malignancy, prior radiation or chemotherapy, autoimmune disease, and prior ovarian operation. In addition, ovarian pathology such as endometriomas, dermoid cysts, and other cystic masses of the ovary bigger than 2 cm also excluded women from participation, as did a solid ovarian mass of any size. Participants were required to be premenopausal (clinically defined). For the purpose of this investigation, women with amenorrhea of more than 3 months' duration were not enrolled to avoid enrolling women who had experienced their FMP. All participants underwent the ultrasound examination and venipuncture within 2 weeks of scheduled surgical operation. The authors were not involved in the decision to perform surgical operation, nor the operation itself. If both ovaries were removed from a participant, the ovary best visualized on transvaginal ultrasound examination was selected for histological determination of the ovarian PF and NGF count. If a single ovary was removed, it was processed for the determination of the follicle count. Prior investigations have demonstrated a strong correlation in the ovarian PF and NGF count between the two ovaries constituting a pair. 18 At the University of Oklahoma, participants were compensated $50 for the time required to undergo the ultrasound examination and venipuncture and to complete consent documents. This investigation was approved by the Universities of Oklahoma and Washington institutional review boards.
Transvaginal ultrasound examinations for the determination of ovarian AFC
All ultrasound examinations were performed by a single investigator (K.R.H.) using a Philips (Andover, MA) EnVisor or HD-7 ultrasound machine with a C8-4v vaginal transducer. All follicles 2 to 10 mm in size were considered to be antral follicles. The total number of antral follicles for each ovary was identified and recorded.
Hormone assays
Inhibin B assays were performed with a solid-phase sandwich enzyme-linked immunosorbent assay (ELISA; Inhibin B Gen II ELISA, Beckman Coulter, Inc., Brea, CA) by Quest Diagnostics (San Juan Capistrano, CA). The limit of detection with this assay is 2.6 pg/mL, and the limit of quantitation was 10 pg/mL. At 19 pg/mL, the combined intra-assay and interassay coefficient of variation was 6.8%, and at 275 pg/mL, the combined intra-assay and interassay coefficient of variation was 4.3%. Values below quantitative thresholds (the lower limit for reporting a result as set by the commercial laboratory) were given half of the threshold value in analyses.
The immunoassay for estradiol was performed using an Immulite autoanalyzer with reagents supplied by Siemens (Deerfield, IL). The lower limit of detection for the assay is 15 pg/mL. At 46 pg/mL, the intraassay coefficient of variation was 15%, and at 116 pg/mL, the intra-assay coefficient of variation was 9.5%. At 56 pg/mL, the interassay coefficient of variation was 16%, and at 151 pg/mL, the interassay coefficient of variation was 9.3%.
The FSH assay is a solid-phase, two-site chemiluminescent assay with reagents supplied by Siemens using an Immulite autoanalyzer. The lower limit of detection of the assay is 0.1 mIU/mL. At 7.8 mIU/mL, the intra-assay coefficient of variation was 5.4%, and at 42.5 mIU/mL, the intra-assay coefficient of variation was 7.7%. At 8.3 mIU/mL, the interassay coefficient of variation was 8.1%, and at 42.9 mIU/mL, the interassay coefficient of variation was 7.9%.
AMH measurements were performed with a commercially available immuno-enzymometric assay (AMH Gen II ELISA, Beckman Coulter, Inc.) by Quest Diagnostics (Valencia, CA). The limit of detection with this assay is 0.08 ng/mL, and the limit of quantitation is 0.16 ng/mL. At 0.5 ng/mL, the combined intra-assay and interassay coefficient of variation was 14%. At 4.42 ng/mL, the combined intra-assay and interassay coefficient of variation was 7.7%, and at 14 ng/mL, the combined intra-assay and interassay coefficient of variation was 5.8%. Values below quantitative thresholds (the lower limit for reporting a result as set by the commercial laboratory) were given half of the threshold value in analyses.
Tissue preparation, follicle counting, and stereology
Tissue preparation, follicle identification (PF and NGF), and counting were performed using a validated technique combining systematic random sampling and the optical disector as previously described 18, 19 Briefly, the fractionator/ optical disector method is based on directly counting the particles of interest (in this case, the oocyte nucleoli) in a known fraction of the original structure. The total number of nucleoli encountered in this fraction is then multiplied by the inverse of a hierarchy of systematic random sampling fractions to generate an estimate of the total number in the original specimen.
The first sample fraction (F1) consisted of the original ovary minus the small portion previously removed for pathological examination. Each ovary was cut into approximately 1-mm slabs perpendicular to the long axis of the ovary. Approximately eight slabs were selected out of the total generated (yielding a second fraction, F2) using systematic random sampling rules. The selected slabs were dehydrated and embedded as a group in one or two large (2 Â 3 in) blocks of glycol methacrylate (Technovit 8100, Energy Beam Sciences, Inc., Agawam, MA). The blocks were sectioned at a thickness of 25 Km using a rotary microtome. Every 10th section (the third fraction, F3) was collected in the order generated on glass slides for staining. Sections were stained with Richardson stain and then mounted with cover slips using Cytoseal 280 (Stephens Scientific, Kalamazoo, MI).
Sections representing the largest two-dimensional profile of each slab were then selected for counting with the optical disector. The fraction that this section represented from the entire collected stack of sections from each slab (F4) was determined by placing a point grid over the section and summing the points that fell over the sections. This value was then divided by the total number of points landing over all collected sections (including the initial and trailing partial slab fragments encountered at the beginning and end of the sectioning run across each slab).
Optical disector counting frames were placed over the selected stained sections using systematic random sampling rules. 20 Placement of optical disectors and delineation of the areas of interest were accomplished by use of StereoInvestigator software (MicroBright Field, Colchester, MA) operating on a PC style computer coupled to a Nikon (University of Oklahoma) or Zeiss Photomicroscope II (University of Washington). Sequential placement of optical disector frames was performed by a motor-driven microscope stage directed by the Stereo-Investigator software.
The entire cortex of each section in the counting sample was outlined under low magnification for placement of the disector frames. The area of the disector frame divided by the area of the steps between placements (representing a grid) represented a fifth sampling fraction (F5). The next sampling fraction (F6) consisted of the height of the optical disector divided by the height of the tissue section. This fraction accounts for the portion of the tissue section represented by the guard area, in which no counting was performed.
Follicle identification
All follicles were classified according to the morphologic criteria as described by Gougeon. 21 The population of NGFs consisted of primordial (PF), intermediate, and primary follicles (Fig. 2 ). PFs were defined as containing a single layer of flattened granulosa cells; intermediate follicles were defined as a single layer of granulosa cells with at least one cuboidal and one flattened granulosa cell; and primary follicles were defined as containing a single layer of cuboidal granulosa cells without any flattened granulosa cells (Fig. 2) . Raw counts (Q j ) for each class of NGFs were then converted to an estimate of the total number (N) of NGFs in the entire ovary by the following equation (where Q j = number of each class of NGF identified in the fraction of tissue counted):
Statistical analysis
Baseline characteristics, endocrine levels, the ovarian AFC as determined by transvaginal ultrasound examination, and log-transformed ovarian PF and total NGF counts were compared among the stages of the STRAW staging system with one-way analysis of variance. Post hoc comparisons between STRAW stages, endocrine tests, age, and the AFC were performed with the Bonferroni/Dunn method to adjust for multiple comparisons. Trends in ovarian follicle counts and the individual biomarkers of ovarian reserve were determined with linear regression. Statistical analyses were performed with StatView version 5.0.1. A P value of less than 0.05 was considered statistically significant for the initial comparisons and a P value less than 0.0083 was considered significant for the post hoc tests.
RESULTS
The endocrine and AFC results of the participants (n = 63 total; n = 43 for endocrine and AFC measures) are summarized in Table 1 . Box plots of endocrine parameters, the ovarian AFC as determined by transvaginal ultrasound examination, and log10-transformed ovarian primordial and total NGF counts are illustrated in Figure 3 . Although age was significantly different across the STRAW stages (P G 0.0001; Table 1 ), there was no significant difference in age between stages j3, j2, and j1 in post hoc testing (P = 0.68, 0.15, and 0.20 between stages j3 and j2, j3 and j1, and j2 and j1, respectively).
Ovarian PF counts were significantly different across the STRAW stages (P G 0.0001; Fig. 3A) , with significant decreases in PF count noted between each stage in post hoc testing (P G 0.0001 between each stage, with the exception of the difference between stages j2 and j1, where P = 0.0074; test for trend P G 0.0001). Similarly, NGF counts decreased significantly with advancing STRAW stage (P G 0.0001; Fig. 3B ; test for trend P G 0.0001). Differences in ovarian NGF counts were significant between each stage in pairwise comparisons (P G 0.001), with the exception of the difference between stages j2 and j1, where P = 0.015.
Similarly, serum FSH levels (Fig. 3C ) were significantly different among the STRAW stages (P = 0.024), with increasing values associated with more advanced STRAW stage (test for trend P = 0.015). In post hoc testing, only the difference between STRAW stages j4 and j1 reached statistical significance (P = 0.0036). In contrast, estradiol and inhibin B levels were not significantly different across the STRAW stages (P = 0.81 and 0.23, respectively; Table 1 and Fig. 3F ).
The ovarian AFC was significantly different among STRAW stages (P G 0.0001; Fig. 3D) , with a progressive decrease noted with advancing stage (test for trend P G 0.0001). In pairwise comparisons, only the differences between STRAW stages j4 and j3, j4 and j2, and j4 and j1 were statistically significant (P G 0.0001). AMH levels also decreased significantly with advancing STRAW stage (P G 0.0001; Fig. 3E ; test for trend P G 0.0001). In pairwise comparisons, however, these differences were significant only between STRAW stages j4 and j3, j4 and j2, and j4 and j1 (P G 0.0001). Of note, all of the participants in STRAW stage j1 had AMH levels below the limit of quantitation (n = 5), as did 7 of 12 participants in STRAW stage j3 and 14 of 20 participants in STRAW stage j2.
DISCUSSION The creation and validation of a staging system for reproductive aging are of paramount importance in our desire to better counsel women regarding future reproduction and health. For most women, the assertion that menopause will occur at age 51 T 10 years is simply not adequate for family planning and risk assessment. Our desire to better predict menopause is rooted in the understanding that some women will experience an early menopause with the corresponding increased risks for infertility, cardiovascular disease, and osteoporosis. 15, 22, 23 Conversely, others will experience a late menopause, with the possibility of an increased risk for breast and endometrial cancer. 24, 25 To conduct meaningful studies on reproductive aging, it is necessary to have a valid means by which to characterize study populations. Ten years ago, the members of the STRAW workshop proposed a staging system of reproductive aging to address this need with the understanding that future modifications and validation would be necessary.
FIG. 3.
Box plots of log10-transformed ovarian primordial and nongrowing follicle counts, total ovarian antral follicle counts, and biomarkers of ovarian reserve for STRAW stages j4 through j1. A: Log10 primordial follicle count: P G 0.0001 between all stages except j2/j1, where P = 0.0074. B: Log10 nongrowing follicle count: P G 0.0001 between all stages except j2/j1, where P = 0.015. C: FSH: P = 0.0036 between stages j4 and j1; all others are not significantly different. D: Antral follicle count: P G 0.0001 between all stages except j3/j2, j3/j1, and j2/j1, which are not significantly different. E: AMH: P G 0.0001 between all stages except j3/j2, j3/j1, and j2/j1, which are not significantly different. F: inhibin B: ANOVA not significant (P = 0.23). STRAW, Stages of Reproductive Aging Workshop; FSH, follicle-stimulating hormone; AMH, antimüllerian hormone; ANOVA, analysis of variance.
In this investigation, we have identified significant differences in the ovarian PF count between STRAW stages as defined by menstrual cycle characteristics. Given that Richardson et al 26 identified lower ovarian PF counts in women with cycle irregularity compared with those with regular menstrual cycles, the decrease in PF count associated with irregular cycles themselves was anticipated. The important aspect of this investigation is the demonstration that progressively decreasing PF counts are associated with advancement through the STRAW stages as defined by menstrual cycle characteristics, each representing a window of time before menopause. Thus, this investigation represents an important step in the validation of the STRAW staging system. In addition, ovarian PF counts were significantly different between stages j3, j2, and j1, whereas age was not significantly different between these groups. Therefore, STRAW stage as defined by menstrual cycle characteristics provides information regarding the ovarian reserve above and beyond age alone.
We were unable to include serum levels of FSH to categorize women into the specific STRAW stages, as levels were obtained irrespective of cycle day because of the short time frame between enrollment and surgical operation. As a result, only menstrual cycle characteristics were used to classify women into the STRAW stages. Given that the only distinction between STRAW stages j4 and j3 is an increased early follicular phase FSH level, we cannot exclude the possibility that some of the participants categorized as stage j3 could have had normal early follicular phase FSH levels and should have been categorized as stage j4. Nevertheless, the average age of the women in stage j3 was 45.4 years, an age that would typically be considered beyond the Bpeak[ reproductive years (stage j4).
Although we were able to detect significant differences in the ovarian PF count between the STRAW stages in this investigation, determining ovarian PF counts with modern morphometric techniques is strictly a research tool, not a clinical assay. Therefore, considerable efforts have been put forth into identifying biomarkers that would be useful in predicting age at menopause and could be incorporated into a clinical staging system of reproductive aging. Perhaps the most promising of these markers are serum levels of AMH and the ovarian AFC as assessed by transvaginal ultrasound examination. Both are strongly correlated with the ovarian PF and NGF count, 27 the true measures of ovarian reserve, and both are known to decline with chronological age in cross-sectional and some longitudinal investigations. 28<32 Furthermore, unlike serum levels of FSH, inhibin B, and estradiol, serum levels of AMH and the ovarian AFC seem to be largely independent of cycle phase. 33, 34 To contrast the observed differences in the ovarian PF and NGF count with biomarkers of ovarian reserve, we measured serum levels of AMH, inhibin B, FSH, and estradiol and determined the ovarian AFC in a subset of the participants. Although we detected significant differences in serum levels of AMH, FSH, and the ovarian AFC across the STRAW stages, we were unable to detect significant differences in pairwise analyses for any of the biomarkers between stages j3, j2, and j1.
Other investigations, however, have identified significant differences in AMH 11 and FSH 13 levels between all STRAW stages. Possible explanations for the discrepancy between our findings and those of other investigators include our smaller sample size and, in the case of FSH, the lack of cycle phaseY specific measurements. In addition, the currently available commercial assay for AMH (AMH Gen II ELISA, Beckman Coulter; 0.08 ng/mL) has a much higher limit of detection than the prior assay used in the Hale et al 11 investigation (Diagnostic Systems Laboratories, Inc., Webster, TX; 0.017 ng/mL). The lack of sensitivity of the current assay suggests that AMH levels may be less useful in models forecasting age at FMP when an individual is at more advanced stages of reproductive age (eg, STRAW stages j2 and j1). Conversely, other longitudinal investigations have demonstrated that AMH exhibits more consistent changes over time than do the ovarian AFC and serum levels of FSH and inhibin B in younger reproductive-aged women. 30 Therefore, serum levels of AMH may be more useful in predicting age at menopause when an individual is at a less advanced stage of reproductive age. Indeed, a recent longitudinal investigation has demonstrated reasonable agreement between the predicted and observed age of menopause with serum levels of AMH measured~6 years before the FMP. 35 Additional prospective longitudinal studies are needed to confirm these findings.
Serum inhibin B and estradiol concentrations were not significantly different across the STRAW stages in this investigation. Investigations of others, however, have identified significant differences in these hormones across the STRAW stages, although not between all stages in pairwise comparisons. 11, 13 As with serum measurements of FSH, it seems probable that the lack of significant differences in inhibin B and estradiol levels between the STRAW stages in this investigation are caused by the smaller sample size and the lack of cycle dayYspecific measurements.
In considering the relative value of determining ovarian PF and NGF counts to validate the STRAW staging system as well as to investigate the fundamental aspects of reproductive aging, it is useful to review the strengths and limitations of the study design. The strength of an investigation of this nature includes the fact that the major dependent variable of interest, the true ovarian reserve, is what is being measured. Studies using the FMP as the outcome of interest rely on another organ, the uterus, for a lack of uterine bleeding. In effect, the FMP is a surrogate marker for ovarian follicle depletion. Although the FMP would seem to be a reasonable marker in most cases, some women may cease having menstrual cycles for reasons other than follicle depletion (eg, because of thyroid, hypothalamic, or pituitary dysfunction). Similarly, vaginal bleeding may persist beyond follicle depletion in some women (eg, because of estrogen production from adipose tissue). In addition, longitudinal studies investigating age at FMP can only identify this event 1 year after it has passed. Therefore, longitudinal studies are time-consuming and expensive relative to investigations using ovarian follicle counts as the outcome of interest.
Given that counts of ovarian PFs and NGFs are direct measures of the ovarian reserve, it is not unexpected that these measures would have more discriminatory power between the STRAW stages than would any of the proposed biomarkers.
The limitations of using PF and NGF counts as the best indicator of ovarian aging include the fact that these studies can only be cross-sectional by their very nature. Furthermore, the argument can be made that women undergoing surgical removal of the uterus and ovaries cannot be considered Bnormal,[ and thus, it may not be appropriate to extrapolate the results to the general population. Although processing ovaries for determination of the ovarian PF and NGF count with modern morphometric techniques is relatively quick and inexpensive, obtaining appropriate clinical specimens is timeconsuming and difficult. This is particularly true at the more advanced stages of reproductive age, wherein indications for surgical operation are rare. Finally, our study design relies on the participants' recall of menstrual cycle characteristics, which may be inaccurate. 36, 37 Nevertheless, the recollection of menstrual cycle characteristics would seem to generally be adequate in a clinical situation wherein a staging system of reproductive aging would be used.
Although this investigation makes progress toward the validation of the STRAW staging system, the lack of specific Bcut points[ for categorizing an individual into one stage versus another based on biomarkers highlights the limitations of our current knowledge. Examining endocrine, ultrasound, and even advanced anatomical data is useful for categorizing groups but not individuals into a specific stage. Future large prospective studies examining changes in AMH and the ovarian AFC associated with the distinct stages of the STRAW staging system and the development of more sensitive AMH assays may be useful in this regard.
CONCLUSIONS
The present study demonstrates that significant differences in the ovarian PF count exist between the different stages of the STRAW staging system as defined by menstrual cycle characteristics. This finding suggests that the progressive STRAW stages do represent distinct and progressively more advanced stages of reproductive age. Considerable overlap exists between the STRAW stages in the levels of the ovarian and peripheral biomarkers of reproductive age evaluated in this investigation. As such, these markers currently have limited utility in categorizing individuals into a particular STRAW stage and ultimately forecasting the age of depletion of the ovarian reserve. From a practical standpoint, models and staging systems that forecast the age of the FMP would be most useful if they could identify the age of the FMP at a relatively young age rather than when ovarian failure is imminent. AMH may be the most promising biomarker in this regard. Further longitudinal research is needed to characterize the decline in this hormone and other biomarkers associated with reproductive aging.
